HRMY Stock Forecast & Price Target

Harmony Biosciences Hldgs is supported by the durability of WAKIX, with 2026 net revenue guidance reaffirmed at $1.00 billion–$1.04 billion versus $1.03 billion FactSet consensus, after 2Q26 net revenue of $261.3 million and about 8,950 average patients on therapy. Its positive outlook is further reinforced by a cash-rich balance sheet of $962.5 million and a pipeline that includes pitolisant, BP-205, Zygel, and EPX-100, giving it multiple shots at growth beyond the core franchise. The orderly CEO transition to Peter Anastasiou on January 1, 2027, with Jeffrey Dayno advising through 2027, also supports strategic continuity while the company advances clinical milestones and protects WAKIX exclusivity.

Harmony Biosciences Hldgs is facing a concentrated risk profile because WAKIX, its main commercial product, remains exposed to sodium oxybate competition, slower-than-expected new patient adds, and earlier-than-expected generic pitolisant entry. The pipeline does not fully offset that dependence, as clinical development uncertainty remains high across pitolisant GR/HD, EPX-100, and other programs, while commercialization, reimbursement, pricing, and litigation risks add further execution pressure. Even with a $3.2 billion firm value under a 12% discount rate and 6.0x terminal multiple, the outlook stays negative because success probabilities of 60% for pitolisant programs and 80% for EPX-100 still leave meaningful downside if trials or market adoption disappoint.